2,382
Participants
Start Date
April 15, 2025
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Atorvastatin
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
Simvastatin
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
Rozuvastatin
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
Ezetimibe
Ezetimibe
Niacin
Niacin
Ciprofibrate
Fibrates
Fenofibrate
Fibrates
Bezafibrate
Fibrates
Evolocumab
PCSK9 inhibitor
Alirocumab
PCSK9 inhibitor
Inclisiran
Small interfering RNA
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Kaluga
RECRUITING
Novartis Investigative Site, Ryazan
RECRUITING
Novartis Investigative Site, Voronezh
RECRUITING
Novartis Investigative Site, Chelyabinsk
RECRUITING
Novartis Investigative Site, Chelyabinsk
RECRUITING
Novartis Investigative Site, Vladimir
RECRUITING
Novartis Investigative Site, Perm
RECRUITING
Novartis Investigative Site, Yekaterinburg
RECRUITING
Novartis Investigative Site, Yekaterinburg
RECRUITING
Novartis Investigative Site, Tyumen
RECRUITING
Novartis Investigative Site, Surgut
RECRUITING
Novartis Investigative Site, Tomsk
RECRUITING
Novartis Investigative Site, Omsk
RECRUITING
Novartis Investigative Site, Kemerovo
RECRUITING
Novartis Investigative Site, Yakutsk
RECRUITING
Novartis Investigative Site, Krasnoyarsk
RECRUITING
Novartis Investigative Site, Vladivostok
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY